Immunic exercises exclusive IMU-856 global license option from Daiichi
Category: #health  By Mateen Dalal  Date: 2020-01-10
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Immunic exercises exclusive IMU-856 global license option from Daiichi

Immunic, a renowned biopharmaceutical company focused on treating autoimmune and chronic inflammatory diseases, reportedly announced that its subsidiary, Immunic AG, has implemented its exclusive global license option for a group of compounds that are designated by it as IMU-856.

The company exercised this option under the terms of its license agreement and existing option with Japanese pharmaceutical company, Daiichi Sankyo.

The company plans to initiate a phase 1 clinical trial for this novel program during the first half of 2020. The IMU-856 is a small molecule, orally available modulator that aims at a yet undisclosed protein that works like a transcriptional regulator for the intestinal barrier function.

IMU-856 signifies a novel and potentially disruptive method to treat intestinal diseases. the molecule also is capable of restoring the intestinal barrier function and it would also maintain immunocompetency.

President and Chief Executive Officer of Immunic, Daniel Vitt, Ph.D., stated that practicing this option is a vital milestone, as it signifies that the company is convinced about the IMU-856’s preclinical safety profile. Further, the company is ready to move ahead and take the program in phase 1 clinical studies, which it intends to start in the first half of 2020.  

Vitt further added that the company’s recently showcased preclinical information reinforced its belief that IMU-856 has disease-modifying features for several intestinal diseases and shows potential significant benefits on present immunosuppressive therapies which tackles inflammation while unintentionally reducing the immune surveillance of the body.

Vitt also added that the company is hopeful that this phase 1, multiple and single ascending dose trials would serve as a vital step for IMU-856’s development as a safe therapy option for patients with gastrointestinal diseases through restoring intestinal barrier function without impairing the patient’s immune system.

Senior Executive Officer and Global Head of R&D at Daiichi Sankyo, Junichi Koga stated that the company is pleased that Immunic exercised the option for IMU-856. The company is dedicated to providing innovative medicines to patients throughout the world as fast as possible, either by itself or from strategic partnerships.

Koga further added that the company is confident that Immunic is its best partner and would quickly propel the development of this new compound for patients suffering from intestinal diseases.

 

Source credit: https://www.immunic-therapeutics.com/2020/01/08/immunic-exercises-its-option-for-the-exclusive-worldwide-license-to-imu-856-from-daiichi-sankyo-co-ltd/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

EVs could capture 50% revenue share of major markets by 2030: Report

EVs could capture 50% revenue share of major markets by 2030: Report

By Mateen Dalal

According to a report provided by KPMG, more than 50% of the total vehicle sales will be controlled by the EV segment by 2030. Electric vehicles are rapidly gaining a large share in the mainstream global automobile market. With electric two-wheelers...

Tesla app outage led to several drivers being locked out of their cars

Tesla app outage led to several drivers being locked out of their cars

By Mateen Dalal

Several owners took to social media to vent out as they were unable to utilize their vehicles due to the app outage. CEO Elon Musk has apologized and guaranteed that it does not re-occur in the future. Several Tesla owners were reportedly una...

EU lawmakers agree on new terms for regulating Big Tech companies

EU lawmakers agree on new terms for regulating Big Tech companies

By Mateen Dalal

European Union lawmakers have reportedly settled on new terms for targeting Big Tech companies, an effort to reduce anti-competitive practices in the digital world. According to sources, major political parties in the European Parliament agreed to a...